期刊文献+

一锅法制备抗肿瘤药对甲苯磺酸索拉非尼 被引量:8

One-pot synthesis of anticancer drug sorafenib tosylate
原文传递
导出
摘要 目的研究分子靶向抗肿瘤药对甲苯磺酸索拉非尼(1)的简便合成工艺。方法以3-三氟甲基-4-氯苯胺(2)为起始原料,首先在三光气的二氯甲烷或2-甲基四氢呋喃溶液中,在二异丙基乙基胺存在下,制得相应的异氰酸酯(2′);然后在二异丙基乙基胺存在下,与4-(4-氨基苯氧基)-N-甲基-2-吡啶甲酰胺(3)成脲,一锅法合成索拉非尼(4);最后与对甲苯磺酸成盐得到目标化合物。结果以二氯甲烷为溶剂,使用安全易得的三光气,制得索拉非尼的收率为84%,目标物的收率为91%;以绿色溶剂2-甲基四氢呋喃替代二氯甲烷,制得索拉非尼的收率为85%,目标物的收率为96%。结论该工艺路线操作简便,反应时间短,无需分离高反应活性的中间体,收率较高,绿色环保。 Aim To develop a facile process for the molecular-targeted anticancer drug sorafenib tosylate(1).Methods The target product was prepared from 4-chloro-3-trifluoromethylaniline(2),which was transformed into the corresponding isocyanate(2′) in dichloromethane or 2-methyltetrahydrofunan solution of triphosgene in the presence of diisopropylethylamine.Then 2′ reacted with 4-(4-aminophenoxy)-N-methyl-2-pyridinecarboxamide(3) in the presence of diisopropylethylamine to give the unsymmetrical diaryl urea sorafenib(4) in one pot.Compound 4 was finally reacted with p-toluenesulfonic acid to deliver sorafenib tosylate(1).Results Employing dichloromethane as the solvent and triphosgene as the safe and green substitute for highly toxic phosgene,sorafenib(4) was obtained in 84% yield,which was transformed into its tosylate 1 in 91% yield.The halogenated solvent was then successfully substituted in comparable yield of 85% by the green solvent 2-methyltetrahydrofunan to obtain 4,which was transformed into 1 in 96% yield.Conclusion This one-pot process of sorafenib(4) features simple operations,short reaction time,no separation of reactive intermediate,good yield and green chemistry.
出处 《中国药物化学杂志》 CAS CSCD 2010年第5期358-361,共4页 Chinese Journal of Medicinal Chemistry
基金 上海市基础研究重点项目(09JC1413200) 国家"重大新药创制"科技重大专项(2009ZX09301-007)
关键词 索拉非尼 合成工艺 三光气 靶向药物 抗肿瘤药 多激酶抑制剂 sorafenib synthetic process triphosgene targeted drug anticancer drug multikinase inhibitor
  • 相关文献

参考文献10

  • 1Onyx Pharmaceuticals, Inc. , Bayer Health Care Pharmaceuticals, Inc. Nexavar was the first targeted thera- py indicated for the treatment of patients with advanced renal cell carcinoma(RCC). Now, Nexavar isthe first and only systemic treatment proven to extend survival in patients with unresectable HCC [ EB/ OL]. [ 2010 -04 - 12 ]. http://www, nexavar-us. com/scdpts/pages/en/home/hcp/index, php.
  • 2WILHELM S M,CARTER C,TANG L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor acti- vity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progres- sion and angiogenesis [ J ]. Cancer Res, 2004, 64 (19) :7099-7109.
  • 3BANKSTON D, DUMAS J, NATERO R, et al. A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer [ J ]. Org Process Res Dev,2002,6 ( 6 ) :777 - 781.
  • 4赵乘有,陈林捷,许煦,罗晓燕,冀亚飞.对甲苯磺酸索拉非尼的合成[J].中国医药工业杂志,2007,38(9):614-616. 被引量:15
  • 5LOGERS M, GEHRING R, KUHN O, et al. Process for the preparation of 4-{ 4-[ ( { [4-chloro-3-( uifluoromethyl) phenyl ] amino } 4-carbonyl ) amino ] phenoxy t -N-methylpyridine-2-carboxamide: US, 2008/ 0262236 [ P]. 2008 - 10 - 23.
  • 6ROSSETrO P,MACDONALD P L,CANAVESI A. Process for the preparation of sorafenib and salts thereof:WO,2009/111061 [P]. 2009 -09 - 11.
  • 7SCHETTY G, STAMMBACH W, ZINKERNAGEL R. Insecticidal derivatives of diphenyl urea: US, 2745874 [ P]. 1956 - 05 - 15.
  • 8MAJER P, RANDAD R S. A safe and efficient method for preparation of N, N'-unsymmetrically disubstituted ureas utilizing triphosgene [ J ]. J Org Chem, 1994,59(7) : 1937 - 1938.
  • 9杜晓华,许响生,徐振元.一种安全有效的合成芳基异氰酸酯的方法[J].农药学学报,2002,4(4):83-85. 被引量:24
  • 10AYCOCK D F. Solvent applications of 2-methyltetrahydrofurah in organometallic and biphasic reactions [J]. Org Process Res Dev,2007,11(1) :156 -159.

二级参考文献16

  • 1王绪根,谭心舜.异氰酸酯的反应动力学研究[J].青岛科技大学学报(自然科学版),2005,26(5):382-385. 被引量:6
  • 2钟敏.未来的重磅炸弹级药物[J].上海医药,2006,27(2):80-83. 被引量:3
  • 3吕允凤,封宇飞,胡欣,毕开顺.索拉非尼的药理及临床研究[J].中国新药杂志,2007,16(1):88-91. 被引量:16
  • 4李乔生,朱德宝,杨用娟.有机异氰酸酯 [A].<化工百科全书>编辑委员会,化学工业出版社<化工百科全书>编辑部.<化工百科全书> [M]. 北京:化学工业出版社,1998, 19: 209-211.
  • 5a) Ramsperger H C, Waddington G. The kinetics of the thermal decomposition of trichloromethyl chloroformate [J]. J Am Chem Soc, 1933, 55: 214.b) Kurita K, Matsuma T, Iwakura Y. Trichloromethyl chloroformate: reaction with amines, amino acids, and amino alcohols [J]. J Org Chem, 1976, 41: 2070.c) Kurita K, Iwakura Y. Trichloromethyl chloroformate as a phosgene equivalent: 3-isocyanatopropanoyl [J]. Org Synth, 1979, 59: 195.
  • 6Eckert H, Foster B. Triphosgene: a crystalline phosgene equivalent [J]. Angew Chem, Int Ed Engl, 1987, 26: 894.
  • 7Roussel-UCLAF. Herbicidal cyclic compounds containing urea groups [P]. France: FR 2241248,1975-2-31. (CA: 1975, 83: 131605n)
  • 8Guillot J C, Wetroff G, Debourge J C, et al. Fungicidal chloroacetone oxime phenylcarbamates [P]. Germany: DE 2434821, 1975-2-13. (CA: 1975, 83: 78927r)
  • 9Siefken W. Polyurethans. IV. Mono-and polyisocyanates [J]. Ann, 1949, 562: 75-136.
  • 10Werntz J H. Fluorine-substituted aromatic isocyanates [P]. USA: US 2625561, 1953-1-13. (CA: 1953, 47: 11243 d)

共引文献37

同被引文献67

  • 1刘亚方,李小刚,李洪玉,李金岭,姜申德.索拉非尼的合成研究[J].精细化工中间体,2012,42(5):36-39. 被引量:6
  • 2吕允凤,封宇飞,胡欣,毕开顺.索拉非尼的药理及临床研究[J].中国新药杂志,2007,16(1):88-91. 被引量:16
  • 3赵乘有,陈林捷,许煦,罗晓燕,冀亚飞.对甲苯磺酸索拉非尼的合成[J].中国医药工业杂志,2007,38(9):614-616. 被引量:15
  • 4Scott W, Christopher C, Mark L, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer [J]. Nat Rev Drug Discov, 2006, 5 (10) : 835-844.
  • 5Donald B, Jacques D, Reina N, et al. A scaleable synthesis of BAY 43-9006: A potent Raf kinase inhibitor for the treatment of cancer J]. Org Process Res Dev, 2002, 6: 777-781.
  • 6Riedl B, Dumas J, Khire U, et al. Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors: US, 7235576 [P]. 2007-06-26.
  • 7刘新科.一种环境友好的索拉非尼中间体制备方法:中国,101302193[P].2008.11-12.
  • 8Buchstaller HP, Finsinger D, Stieber F, et al. Preparation of aryl semicarbazide derivatives as kinase inhibitors: WO, 2005082853 EP]. 2005-09-09.
  • 9Rossetto P, Macdonald PL, Canavesi A. Process for preparation of sorafenib and intermediates thereof: WO, 2009111061 EP]. 2009-09-11.
  • 10Muddasani PR, Nannapaneni VV. Economically and commercially viable process for the preparation of sorafenib: WO, 2009054004 [P]. 2009-04-30.

引证文献8

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部